GlassScriptPhysician profile
Jeffrey Lehman
NPI 1548261399
$3,441.26
in general payments reported to CMS, 2019-2025
19 companies · $1,090 in 2025
The $1,090 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $144 · 2020: $41.15 · 2021: $101 · 2022: $178 · 2023: $912 · 2024: $974 · 2025: $1,090.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,890 · Education: $86.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,889.60 |
| Education | $86.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $636.21 | 2019-2025 | Fasenra, Breztri, Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $569.73 | 2022-2025 | Cuvitru, Hyqvia |
| Csl Behring | $546.30 | 2023-2025 | Hizentra, Haegarda, Andembry |
| Glaxosmithkline, LLC. | $336.29 | 2021-2024 | Trelegy Ellipta, Nucala, Arexvy |
| Genentech USA, INC. | $305.32 | 2019-2025 | Xolair |
| Regeneron Healthcare Solutions, INC. | $277.79 | 2023-2025 | Dupixent |
| Grifols USA, LLC | $150.60 | 2020-2025 | Xembify |
| Novartis Pharmaceuticals Corporation | $105.35 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $99.81 | 2021-2023 | Verquvo |
| Optinose US, INC. | $95.09 | 2021-2025 | |
| Genzyme Corporation | $88.30 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.18 | 2019-2022 | |
| Biocryst US Sales Co., LLC | $45.34 | 2022-2025 | Orladeyo |
| Genentech, INC. | $39.27 | 2024 | Xolair |
| Pharming Healthcare, INC. | $26.00 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ionis Pharmaceuticals, INC. | $21.46 | 2025 | Dawnzera |
| Pfizer INC. | $16.82 | 2019 | |
| Aimmune Therapeutics, INC. | $15.10 | 2022 | |
| Alk-Abello, INC | $11.30 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Lehman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.